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ACEi/ARBs users vs. non-users (5.3% vs. 5.3%, p = 1.000). On 
univariate analysis, higher V20 (p = 0.00071), centrally 
located tumors (p = 0.00025), and higher baseline FEV1 
percentage (p = 0.03577) were associated with increased 
incidence of RP. On multivariate analysis, both higher V20 (p 
<0.0001) and centrally located tumors (p = 0.0094) were 
associated with increased incidence of RP. There was no 
identifiable relationship between age, gender, ethnicity, BMI, 
KPS, Charlson comorbidity score, smoking status or history, 
chemotherapy prior to or post SBRT, baseline DLCO, and total 
radiation dose or fractionation with the incidence of RP. 
Conclusions: The use of ACEi/ARBs at the time of lung SBRT 
did not demonstrate a significant association with the 
incidence of symptomatic RP despite previously reported 
data suggesting the opposite. Higher V20’s and centrally 
located tumors, however, were associated with increased 
incidence of RP. Given conflicting data of the protective 
effects an ACEi/ARBs may have against RP, a prospective 
evaluation is necessary.  
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Purpose/Objective: To evaluate the role of coregistered 
4DPET/CT for SBRT target delineation in patients with central 
and peripheral lung tumors. 
Materials and Methods: Analysis of internal target volume 
(ITV) delineation of central and peripheral lung lesions 
(classified according to EORTC 2211-081133) in 21 patients 
treated with SBRT. Manual delineation was performed by 4 
observers in 2 sequential contouring phases: first on 
respiratory gated 4DCT with a diagnostic 3DPET/CT available 
aside (CT-ITV) and secondly on coregistered 4DPET/CT 
(PET/CT-ITV). Comparative analysis of volumes and inter-
reader agreement was carried out for both contouring 
sessions.  
Results: Eleven cases of peripheral and 10 central lesions 
were evaluated. In peripheral lesions, CT-ITV was 6.2 cm3 
and PET/CT-ITV 8.6 cm3, with a small but significant average 
volume increase (p<0.05) resembling a mean change in 
hypothetical radius of 2 mm. For both CT-ITVs and PET/CT-
ITVs inter reader agreement was good and unchanged (0.733 
and 0.716; p=0.58). All PET/CT-ITVs stayed within the PTVs 
derived from CT-ITVs.  
In central lesions, average CT-ITVs were 42.1 cm3, PET/CT-
ITVs 44.2 cm3 with statistically not significant volume and 
hypothetical radius changes. However, inter-reader 
agreement improved significantly (0.665 and 0.750; p<0.05). 
Furthermore, 2/10 PET/CT-ITVs exceeded the PTVs derived 
from CT-ITVs by several ml. 
 
 
Conclusions: The addition of coregistered 4D-PET data to 4D-
CT based target volume delineation for SBRT of centrally 
located lung tumors increases the inter-observer agreement 
and may help in avoiding geographic misses. Hence, it may 
improve treatment accuracy and normal tissue sparing. This 
chance should be further evaluated prospectively.  
   
 
Poster Discussion: Young Scientists 3: Breast cancer  
 
 
PD-0430   
Results from the radiotherapy quality assurance 
programme for the FAST-Forward breast trial 
R. Zotova1, J. Yarnold2, D. Wheatley3, C. Griffin4, B. Murray5 
1Mount Vernon Cancer Centre, Radiotherapy Physics, 
Northwood, United Kingdom  
2Royal Marsden Hospital, Institute of Cancer Research, 
London, United Kingdom  
3Royal Cornwall Hospital, Clinical Oncology, Truro, United 
Kingdom  
4Institute of Cancer Research, Clinical Trials Statistical Unit, 
London, United Kingdom  
5Royal Stoke University Hospital, Clinical Oncology, Stoke-on-
Trent, United Kingdom  
 
Purpose/Objective: The purpose of this study is to analyse 
the radiotherapy (RT) treatment plans collected in the FAST-
Forward trial to ensure consistency of treatment across all 
centres and compliance with trial protocol. 
FAST-Forward is a multicentre phase III trial comparing a 1-
week course of curative whole breast RT against a standard 
3-week schedule in terms of local control and late toxicity in 
patients with early breast cancer.  
Materials and Methods: A comprehensive set of dose 
objectives for the breast PTV and organs at risk were defined 
for the trial and protocol compliance was assessed against 
these. The dose distribution should fulfil the following 
criteria: 
- PTV V95%≥90%  
- PTV V105%≤7%  
- PTV V107%≤2% 
- Dmax≤110% 
- Ipsilateral lung V30%≤17% 
- Heart V25%≤5% and V5%≤30%  
The analysis was based on a full 3D RT data review for a 
minimum of 10 randomly selected plans from each site, and 
the rest were based on evaluation of the plan assessment 
forms, completed by centres for each patient. Evaluation 
structure compliance was also checked for the reviewed 3D 
datasets. 
Results: The main trial closed after recruiting 4110 patients. 
To date, 3200 plans (78% of recruited patients) from 47 
centres have been collected. 2400 of these have been 
analysed, with full 3D RT data reviewed for 600 (25%) of 
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these. Retrospective reviews are still in progress, with all 
remaining data to be collected and analysed by the end of 
2014.  
A total of 84 objectives were not met in 63 plans (2.7% of all 
reviewed data), with 14 plans breaching more than one 
objective. The breakdown of all objectives not achieved as a 
percentage of the total number of cases with variations is 
presented below.  
 
 
On further examination 37 of the variations were in 
challenging cases, where clinical compromises were deemed 
necessary by the site principal investigator. In 8 plans a 
higher absolute dose maximum was accepted to a non-
clinically significant volume, as the V105% and V107% 
constraints were met. In 11 plans variations were due to 
misinterpretation of the DVH information at the investigator 
site and/or incorrect contouring of evaluation structures; in 
further 7 plans the reason was not clear. Therefore in 18 
plans (0.8% of all reviewed data) it may have been possible to 
improve the distribution to comply with protocol. 
The observed parameters varied across centres, which is 
attributed to different equipment, planning system and 
technique used. The differences in the median values for 
each dose objective across all centres is summarised below. 
 
 
Conclusions: The review performed on 2400 plans in the 
FAST-Forward trial demonstrates that the majority of plans 
comply with the dose objectives specified in the protocol, 
with only 2.7% of all reviewed data not achieving one or more 
of the dose objectives.  
The FAST-Forward trial is sponsored by the Institute of 
Cancer Research under the National Institute for Health 
Research – Health Technology Assessment programme 
(09/01/47) ISRCTN19906132 
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Purpose/Objective: The 'Utrecht cohort for Multiple BREast 
cancer intervention studies and Long-term evaLuAtion' 
(UMBRELLA) is a Dutch breast cancer cohort, aiming to gain 
insight into physical and emotional symptoms during and 
after breast cancer treatment and to evaluate (multiple) 
experimental interventions (e.g. novel radiotherapy 
treatments, physical activity interventions). In UMBRELLA the 
occurrence of breast edema is monitored, which can cause 
symptoms and decrease quality of life. The objective of this 
observational study is to evaluate prevalence, risk factors, 
edema-related toxicity and consequences of acute and 
chronic breast edema after surgery (i.e. lumpectomy, 
mastectomy, oncoplastic techniques, axillary lymph node 
dissection), irradiation (i.e. local, locoregional, regional) and 
(neo)adjuvant systemic therapy. 
Materials and Methods: As of October 2013, all women with 
breast cancer who are referred to our department of 
Radiation Oncology are invited to participate in UMBRELLA. 
Participants consent to clinical data collection and provide 
‘patient reported outcomes’ at regular time intervals during 
and after treatment. We estimated prevalence of breast 
edema according to CTCAE V4.0 scoring system as registered 
by radiation oncologists at weekly follow-up visits during 
irradiation, and at standard follow-up intervals after 
irradiation. We collected information on potential risk factors 
for edema, such as tumor size, patient characteristics (e.g. 
BMI) and treatment modalities. We performed univariate and 
multivariate logistic regression analysis to identify 
determinants that were (independently) associated with 
breast edema. Patient reported outcomes (i.e. quality of life, 
pain and cosmetic outcome) will be compared for patients 
with and without breast edema. The effect of different 
grades of edema on these patient reported outcomes will also 
be evaluated. 
Results: Between October 2013 and November 2014, 437 
breast cancer patients were enrolled in UMBRELLA. 
Preliminary results after analysis of the first 150 patients 
(median follow-up 49 days) showed that 23% of patients had 
acute breast edema within two months after the start of 
irradiation, of which 97% had ‘mild edema (grade 1)’. The 
proportion of breast edema was higher among patients who 
also received neo-adjuvant chemotherapy (44%), compared to 
21% in those who did not receive neo-adjuvant chemotherapy 
(p=0.024). No other determinants were significantly 
associated with breast edema.  
 
 
